Education
About Us
Working with TipRanks
Follow Us
Springworks Therapeutics (SWTX)
NASDAQ:SWTX
SWTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$28.21 - $62.00
Previous CloseN/A
Volume729.64K
Average Volume (3M)2.37M
Market Cap
$3.56B
Enterprise Value$2.39B
Total Cash (Recent Filing)$69.75M
Total Debt (Recent Filing)$7.91M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
May 01, 2025EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.48
Shares Outstanding74,935,850
10 Day Avg. Volume1,653,349
30 Day Avg. Volume2,365,108
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)19.51
Price to Cash Flow (P/CF)-31.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit13.34
Enterprise Value/Ebitda-8.69
Forecast
1Y Price Target
$71.71Price Target Upside51.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Springworks Therapeutics News
PremiumCompany Announcements
SpringWorks Therapeutics Reports Strong 2024 Performance
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceSWTX reported preliminary 4Q24 and FY24 net product revenue slightly above consensus, highlighting steady growth for Ogsiveo and a fundamentally positive outlook.
Potential AcquisitionMerck KGaA has confirmed discussions with Springworks on a potential acquisition, increasing investor interest.
Regulatory ApprovalsThe FDA announced regulatory U.S. approval of mirdametinib for adult and pediatric patients with neurofibromatosis type 1.
Bears Say
Commercialization RisksRisks include the inability to successfully commercialize nirogacestat and/or mirdametinib, and the failure to expand usage of both within multiple specialty oncology niches.
Financial LossesThe company recorded a net loss of $3.48 per share, which was wider than the original net loss estimate due to greater-than-anticipated operating expenses.
Operating ExpensesThe company recorded a net loss wider than expected due to greater-than-anticipated operating expenses, highlighting financial challenges.
---
Ownership Overview
2.19% Insiders
34.54% Mutual Funds
40.85% Other Institutional Investors
5.69% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SWTX FAQ
What was Springworks Therapeutics’s price range in the past 12 months?
Springworks Therapeutics lowest stock price was $28.21 and its highest was $62.00 in the past 12 months.
What is Springworks Therapeutics’s market cap?
Springworks Therapeutics’s market cap is $3.56B.
When is Springworks Therapeutics’s upcoming earnings report date?
Springworks Therapeutics’s upcoming earnings report date is May 01, 2025 which is in 33 days.
How were Springworks Therapeutics’s earnings last quarter?
Springworks Therapeutics released its earnings results on Feb 20, 2025. The company reported -$1.04 earnings per share for the quarter, missing the consensus estimate of -$0.707 by -$0.333.
Is Springworks Therapeutics overvalued?
According to Wall Street analysts Springworks Therapeutics’s price is currently Undervalued.
Does Springworks Therapeutics pay dividends?
Springworks Therapeutics does not currently pay dividends.
What is Springworks Therapeutics’s EPS estimate?
Springworks Therapeutics’s EPS estimate is -0.77.
How many shares outstanding does Springworks Therapeutics have?
Springworks Therapeutics has 74,935,850 shares outstanding.
What happened to Springworks Therapeutics’s price movement after its last earnings report?
Springworks Therapeutics reported an EPS of -$1.04 in its last earnings report, missing expectations of -$0.707. Following the earnings report the stock price went up 7.536%.
Which hedge fund is a major shareholder of Springworks Therapeutics?
Currently, no hedge funds are holding shares in SWTX
---
Springworks Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$71.71 (51.00% Upside)
$71.71 (51.00% Upside)
Blogger Sentiment
Bullish
SWTX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 7.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.7%
Last 30 Days ▲ 8.4%
Last 30 Days ▲ 8.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.20%
12-Months-Change
Fundamentals
Return on Equity
-46.62%
Trailing 12-Months
Asset Growth
-19.08%
Trailing 12-Months
Company Description
Springworks Therapeutics
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
---
SWTX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call displayed a strong performance for OGSIVEO with significant revenue growth and positive market trends. Expansion efforts into Europe and the promising outlook for mirdametinib contribute to a positive sentiment. However, challenges with the blister pack transition and summer seasonality were noted as short-term hurdles.Read More>---
SWTX Stock 12 Month Forecast
Average Price Target
$71.71
▲(51.00% Upside)
Technical Analysis
Best Analysts Covering SWTX
1 Year
1 Year Success Rate
12/13 ratings generated profit
1 Year Average Return
+67.07%
reiterated a buy rating last month
Copying Yaron Werber's trades and holding each position for 1 Year would result in 92.31% of your transactions generating a profit, with an average return of +67.07% per trade.
---